0000358654
Donate

Reimbursement status:
No reimbursement

Cancer: Multiple myeloma and plasma cell neoplasms

Indication:

Elotuzumab is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

Reimbursement information:

EPAR/SmPC

Details

ATC category :
L01XC
L01XC Monoclonal antibodies
EMA approval status :
Approved
EMA approval date :
2016-05-11
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
Yes